Baseline moderate to severe RV dysfunction was associated with larger LV, lower EF, more severe MR, higher filling pressure, and higher pulmonary artery systolic pressure compared to normal or mildly reduced RV function. Adding SVR to CABG may worsen long-term survival in ischemic cardiomyopathy patients with moderate to severe RV dysfunction
and reduced LV ejection fraction (EF). The SVR hypothesis (Hypothesis 2) of STICH randomized 1,000 patients with anteroapical dysfunction to CABG with SVR versus CABG alone, to test the hypothesis that in patients with LVEF ≤ 35%, CAD amenable to CABG and anterior LV dysfunction, adding SVR improves survival free of subsequent hospitalization for cardiac cause in comparison to CABG alone (8 ) . The concept and technique of surgical ventricular restoration has been well described by Dor et al (9) . The primary outcome of this population has been already reported by Jones et al (10) and the description of clinical characteristics by Zembala et al (11) . Hypothesis 2 patients were followed for a median of 48 months. Only 4 of the 1000 patients withdrew consent for follow up and 6 patients were lost to follow up.
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The present study sought to examine the prevalence of RV dysfunction in those 1,000 patients to determine the relationship between RV dysfunction and other parameters of cardiac structure and function measured by echocardiography. We also examined the interaction of RV dysfunction with treatment on short-term and long-term survival in these patients.
Methods Study Population and Patient Selection
Among the 2,136 patients enrolled into the STICH trial with an LVEF ≤ 35% and CAD amenable to CABG, 1,000 patients with anteroapical dysfunction for which adding an SVR operation to CABG was reasonable but not required were randomized to CABG vs. CABG +SVR. Of the 1000 patients enrolled, 866 patients had a baseline echocardiogram rated as fair to excellent quality (excellent for textbook quality, good for clear definition of RV walls from multiple views, and fair for good definition of RV walls from limited views) for qualitative assessment of RV function by the Echocardiography Core Laboratory (Figure 1 ).
Echocardiography Study
Baseline echocardiography was obtained within 3 months prior to enrollment by clinical sites and sent to the Echocardiography Core Laboratory where each study was initially analyzed by a research sonographer blinded to randomized treatment assignment and clinical outcomes using American Society of Echocardiography guidelines (12) and with a second over-read by a physician. Details of the methodology used for echocardiographic analysis have been previously published (13) .
RV Function Assessment
RV function was assessed prospectively by visual interpretation and categorized as normal, mild, moderate or severe dysfunction. The appreciation of the overall mechanical function of the RV was mainly based on the extent of RV free wall segmental motion, wall thickening, RV cavity size, and subjective assessment of RV area change ( normal >50%, mild 30-50%, moderate 20-30%, and severe <20 % from diastole to systole) RV assessment was derived from the parasternal long axis, apical 4-chamber, and subcostal views. This assessment was based on visual assessment by an experienced Echocardiography Core Laboratory physician (14) .
Once the results of the impact of RV function by visual assessment was known, 40 patients in each group, normal, mild and moderate dysfunction, and all 21 patients with severe RV dysfunction were sent for blinded post-hoc calculation of RV fractional area change. RV fractional area change was calculated from apical four chamber views as [(RV end diastolic area -RV end systolic area)/ RV end diastolic area] by a research sonographer without any knowledge of patient's clinical or other echocardiography data.
Statistics
Clinical and echocardiographice characteristics were described using means and standard deviations for continuous variables and frequencies and percentages for categorical variables.
Due to the limited number of patients with moderate and severe RV dysfunction these two groups have been combined and analyzed as one moderate/severe subgroup. Comparisons of patients across 3 different levels of RV dysfunction (i.e., normal, mild, or moderate/severe)
were performed using Kruskal-Wallis non-parametric analysis of variance on continuous and 
Results
Patients
The study patients (n=866) consisted of 739 men (85%) and 127 women (15%) with a mean age of 62 ± 10 years randomized to CABG alone (n=425) and to CABG + SVR (n=441) (Figure 1 ). At baseline, patients with moderate to severe RV dysfunction had more advanced HF, a higher percentage with atrial fibrillation, a lower percentage with prior myocardial infarction, higher levels of creatinine and BUN, required more diuretic therapy, and walked shorter distances in the 6-minute walk test (Table1).
Prevalence of RV Dysfunction and Its Association
RV function was normal in 686 patients (79%), mildly reduced in 102 patients (12%), and moderately to severely reduced in 78 patients (9%) (Figure 1 ). Of the patients sent for posthoc analyses of RV fractional area change, measurements could only reliably be performed Figure 2 ). In parallel, LVEF was progressively reduced with worsening of RV dysfunction.
All LV diastolic function and filling parameters (E/A ratio, deceleration time, E/e, and LA volume index) were progressively worse with more severe RV dysfunction indicating higher LV filling pressure with worsening RV dysfunction. Mitral regurgitation was more severe and Doppler derived pulmonary artery systolic pressure was higher in patients with moderate to severe RV dysfunction compared to the patients with normal RV function or mild dysfunction ( Table 2 , Figure 3 ).
Prognostic Role of RV Dysfunction
The prognostic effect of RV dysfunction (independent of treatment) was significant for the short-term outcome of 30-day mortality (p=0.023) and for the long-term outcome of death or CV hospitalization (p=0.022). The relationship with long-term mortality did not achieve conventional significance (p=0.070) ( Table 3 ). The nature of these relationships is illustrated with Kaplan-Meier estimates of event rates by degree of RV dysfunction (Figure 3 ), where the highest event rates (worst outcomes) are observed in the patients with moderate to severe RV dysfunction. However, the relationship of RV dysfunction with each of the clinical outcomes considered was no longer significant after adjusting for LVEF and even less so after adjusting for LVEF plus the other prognostic clinical and echo factors (Table 3) .
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Impact of RV Dysfunction on the Treatment Effect of CABG vs. CABG + SVR
For patients with normal or mildly reduced RV function, the outcomes of CABG alone compared to CABG + SVR were not significantly different for either the primary (death or CV hospitalization) or the secondary (death) endpoints ( Figures 4A and 4B ). However, when RV function was moderately or severely reduced, there were significantly higher event rates
for CABG + SVR compared to CABG alone for death or CV hospitalization (p=0.028) and also for death alone (p=0.005) ( Figures 4A and 4B ). There was a statistically significant interaction between RV dysfunction and treatment for the composite endpoint of death or CV hospitalization (p=0.013) and for death alone (p=0.001) due to the markedly higher incidence of clinical outcomes among the patients with moderate/severe RV dysfunction who received CABG + SVR. For the death endpoint, the interaction remained significant even after adjusting for all the other prognostic factors (p=0.022) ( Table 3 ). There also was a worsening trend for CABG + SVR with respect to the short-term outcome of surgical death (30-day mortality). Thirty-day mortality among patients with moderately or severely reduced RV function was 5.9% in CABG alone and 13.6% in CABG + SVR, whereas the corresponding 30-day mortality rates among patients with no or mild RV dysfunction were 5.0% for CABG and 4.7% for CABG + SVR.
Discussion Prevalence of RV Dysfunction and Its Association with LV Remodeling in Ischemic Cardiomyopathy
This is the largest study to evaluate the prevalence and determinants of RV dysfunction in patients with ischemic cardiomyopathy. In the STICH population, 21% of patients had some degree of RV dysfunction and 9% had moderate or severe dysfunction. Progressively more advanced LV remodeling (larger LV volumes, lower EF, and more severe mitral M A N U S C R I P T
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Mechanisms of RV Dysfunction in Ischemic Cardiomyopathy
Several potential underlying mechanisms may explain why progressive RV dysfunction is often accompanied by increasing LV dysfunction (15) . RV dysfunction may reflect primary left ventricular, left atrial, or mitral valve pathology (16, 17) mediated through direct RV compression and the mechanism of RV/LV interdependence or through increased pulmonary pressures and RV afterload due to LV dysfunction (18, 19) . Alternatively, both ventricles might be affected by the same underlying pathological process (CAD) (20) . However, the fact that pulmonary artery systolic pressure was found to increase progressively with worsening of RV systolic function suggests that RV dysfunction is related to functional and hemodynamic abnormalities of the LV. This notion is also supported by a recent study of 
RV Dysfunction and SVR
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The long-term outcome of the patients who received CABG + SVR in STICH was adversely affected when RV function was at least moderately reduced at baseline. The abrupt reduction in LV size and volume may have increased diastolic stiffness and aggravated diastolic function and filling pressure, especially when LV filling pressure was already markedly elevated at baseline in patients with RV dysfunction. Contrary to the initial belief, we have demonstrated that SVR appears to have a greater benefit in patients with an early stage of ischemic cardiomyopathy and less benefit, or even harm, in the patients with a more advanced cardiomyopathy and a larger LV (27) . The worse outcome of SVR in the setting of advanced RV dysfunction confirms the earlier report of worse outcome of SVR in patients with a larger LV and more reduced EF associated with RV dysfunction.
RV Function Assessment
Many 
Study Limitations
In our study, moderate to severe RV dysfunction was found in only 9% of the study patients.
This may underestimate the true prevalence of the degree of RV dysfunction since patients with significant RV dysfunction or pulmonary hypertension might have been excluded by study investigators or surgeons because of a perceived high risk for an operation. The evaluation of RV function that we used was a visual assessment. It is difficult to categorize visual assessment, and our classification may not be easily translated to other laboratories.
However, differentiation of severe RV dysfunction from normal function is relatively easy by visual assessment. More difficult is to determine mild and moderate RV dysfunction.
However, we believe that our observations are clinically relevant as this visual method is the most practical technique in "real life" practice in almost all echocardiography laboratories.
Although the visual assessment of RV function in our study was shown to correlate well with RV fractional area change, fractional area change was measured after the completion of the trial and once the study results with visual assessment were known. This limitation notwithstanding, the measurements of RV fractional area change were performed by blinded readers. Also, as a significant proportion of patients could not have RV fractional area change reliably calculated, it may be that visual assessment, the measure used in this study is the most widely applicable technique for evaluation of RV function in the general population of patients such as those in the STICH trial.
Conclusions
In patients with ischemic cardiomyopathy, RV dysfunction is associated with more advanced LV remodeling, and hemodynamic abnormalities (larger LV volumes, lower EF, higher filling pressure, and more severe MR). The interaction between RV dysfunction and M A N U S C R I P T
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14 treatment is significant for mortality after carefully adjusting for other prognostic clinical and echo factors. When baseline RV function is moderately to severely reduced, the addition of SVR to CABG appears to worsen long-term survival compared to the use of CABG alone. BMI, body mass index; BP, blood pressure; BUN, blood-urine-nitrogen; MI, myocardial infarction; NYHA, New York Heart Association; RV, right ventricular *P-differences between RV dysfunction groups M A N U S C R I P T LVEDV-left ventricular end diastolic volume; LVESV-left ventricular end systolic volume; MR-mitral regurgitation, WMSI-wall motion score index; TR-tricuspid regurgitation; PASP-pulmonary artery systolic pressure; EF-ejection fraction; BSA-body surface area; E-early diastolic velocity; E/A-early/late velocity ratio; LA-left atrium; E/E'-early mitral/annular velocity ratio; E/E'lat ratio; LVED-left ventricular end-diastolic ; LVES-left ventricular end-systolic; DT-deceleration time; RV-right ventricular *P-differences between RV dysfunction groups M A N U S C R I P T 1 Prognostic factors identified from previous modeling analyses were used as adjustment variables for the three different endpoints. Atrial flutter/fibrillation, age, mitral regurgitation, creatinine, hemoglobin, end-systolic volume index, and LVEF were included in the adjustment for all three endpoints. In addition to the factors listed above, previous MI, previous stroke, and NYHA heart failure class were included for both the death endpoint and the death or cardiovascular hospitalization endpoint. CCS angina class was also included in the model for death within 30 days after surgery. Diabetes and hyperlipidemia were also included in the death model. The ability to perform the 6-minute walk test was also included in the death or cardiovascular endpoint model. LVEDV-left ventricular end diastolic volume; LVESV-left ventricular end systolic volume; MR-mitral regurgitation, WMSI-wall motion score index; TR-tricuspid regurgitation; PASP-pulmonary artery systolic pressure; EF-ejection fraction; BSA-body surface area; E-early diastolic velocity; E/A-early/late velocity ratio; LA-left atrium; E/E'-early mitral/annular M A N U S C R I P T
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3 velocity ratio; E/E'lat ratio; LVED-left ventricular end-diastolic ; LVES-left ventricular end-systolic; DT-deceleration time; RV-right ventricular *P-differences between RV dysfunction groups 1 Prognostic factors identified from previous modeling analyses were used as adjustment variables for the three different endpoints. Atrial flutter/fibrillation, age, mitral regurgitation, creatinine, hemoglobin, end-systolic volume index, and LVEF were included in the adjustment for all three endpoints. In addition to the factors listed above, previous MI, previous stroke, and NYHA heart failure class were included for both the death endpoint and the death or cardiovascular hospitalization endpoint. CCS angina class was also included in the model for death within 30 days after surgery. Diabetes and hyperlipidemia were also included in the death model. The ability to perform the 6-minute walk test was also included in the death or cardiovascular endpoint model.
